James, you wrote, "Sunrise most certainly did not flop in any way, shape, or form. The Treatment Arm performed as expected - while the Control Arm blew away all expectations and historical norms going back decades..."
We need some real numbers to establish your assertions here, and I have no recollection of seeing those numbers. I don't remember the "blow away, and going back decades". Without specifics it maybe can be assumed that Bavi performed a couple months better than historical norms for Doce (which makes that part of the pr true) but it did not (apparently) perform better than placebo (which is probably also the case).
It is known that other placebo trials are now "outperforming" THEIR historic norms. That is, for some reason placebos are performing better than ever, and the more convincing the blinding of the placebo controlled study; the more "therapeutic" the treatment environment (e.g. IVs, modern medical equipment); and the more scientific the treatment environment appears to the patient, the better placebo groups seem to do. Finding a difference in the background and therapeutic milieu between Bavi-treated and Doce + placebo will not be easy, and finding Bavi in the placebo is truly a case of lightening striking twice.
If you recall, "spare-the-mice" left this board at about the time we had a healthy discussion here about the possible futility of using an immuno-stimulant such as Bavi with a cytotoxin such as Docetaxel. How can one expect activated monocytes (for instance) to reproduce when cell division is being discouraged and actively reproducing cells are being poisoned? Some stockholders have sat back and said maybe they will be right for all the wrong reasons, which often happens. It was a long shot from the beginning IMO. I'm waiting for Bavi + irradiation; and Bavi-labeled imaging agents, to mention only a couple realistic application for the science.
